Skip to main navigation Skip to search Skip to main content

Comparing different methods for analysing hierarchical composite endpoints: two illustrative case studies with post hoc analyses of the BALANCE (Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness) and CAMERA2 (Combination Antibiotics for methicillin-resistant Staphylococcus aureus) randomized clinical trials

  • Sean W.X. Ong
  • , Ruxandra Pinto
  • , Robert K. Mahar
  • , Neta Petersiel
  • , Robert A. Fowler
  • , Joshua S. Davis
  • , Nick Daneman
  • , Steven Y.C. Tong
  • , David C. Lye
  • , Dafna Yahav
  • , Archana Sud
  • , J. Owen Robinson
  • , Jane Nelson
  • , Sophia Archuleta
  • , Matthew A. Roberts
  • , Alan Cass
  • , David L. Paterson
  • , Hong Foo
  • , Mical Paul
  • , Stephen D. Guy
  • Adrian R. Tramontana, Genevieve B. Walls, Stephen McBride, Narin Bak, Niladri Ghosh, Benjamin A. Rogers, Anna P. Ralph, Jane Davies, Patricia E. Ferguson, Ravindra Dotel, Genevieve L. McKew, Timothy J. Gray, Natasha E. Holmes, Simon Smith, Morgyn S. Warner, Shirin Kalimuddin, Barnaby E. Young, Naomi Runnegar, David N. Andresen, Nicholas A. Anagnostou, Mark D. Chatfield, Allen C. Cheng, Vance G. Fowler, Benjamin P. Howden, Niamh Meagher, David J. Price, Sebastiaan J. van Hal, Matthew V.N.O. Sullivan, Asgar Rishu, Benjamin A. Rogers, Yahya Shehabi, Rachael Parke, Deborah J. Cook, Yaseen Arabi, John Muscedere, Steven Reynolds, Richard Hall, Dhiraj Bhatia Dwivedi, Colin McArthur, Shay McGuinness, Dafna Yahav, Anna Geagea, Pavani Das, Phillip Shin, Michael Detsky, Andrew Morris, Michael Fralick, Jeff Powis, Christopher Kandel, Wendy Sligl, Sean M. Bagshaw, Nishma Singhal, Emilie Belley-Cote, Richard Whitlock, Kosar Khwaja, Susan Morpeth, Alex Kazemi, Tony Williams, Derek MacFadden, Lauralyn McIntyre, Jennifer L.Y. Tsang, Francois Lamontagne, Alex Carignan, John Marshall, Jan O. Friedrich, Rob Cirone, Mark Downing, Christopher Graham, Erick Duan, John Neary, Gerald Evans, Basem Alraddadi, Sameera Aljohani, Claudio Martin, Sameer Elsayed, Ian Ball, François Lauzier, Alexis F. Turgeon, Henry Thomas Stelfox, John Conly, Todd C. Lee, Emily G. McDonald, Richard Sullivan, Jennifer Grant, Ilya Kagan, Paul Young, Cassie Lawrence, Kevin O'Callaghan, Matthew Eustace, Keat Choong, Pierre Aslanian, Ulrike Buehner, Tom Havey, Alexandra Binnie, Josef Prazak, Brenda Reeve, Edward Litton, Sylvain A. Lother, Anand Kumar, Ryan Zarychanski, Tomer Hoffman, David L. Paterson, Peter Daley, Robert J. Commons, Emmanuel Charbonney, Jean Francois Naud, Sally Roberts, Ravindranath Tiruvoipati, Sachin Gupta, Gordon Wood, Omar Shum, Spiros Miyakis, Peter Dodek, Clement Kwok, Linda R. Taggart, Stephanie Smith, Karen Doucette

Research output: Contribution to journalArticlepeer-review

4 Downloads (Pure)

Abstract

Objectives
Hierarchical composite endpoints (HCEs) are increasingly being used in infectious disease research. In this paper, we illustrate different methods for analysing HCEs in post hoc analyses of the Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness (BALANCE) and Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA2) clinical trials.

Methods
We constructed post hoc HCEs for each trial by combining clinical efficacy and safety outcomes: (a) mortality, relapse of bacteraemia, and antibiotic adverse events for BALANCE, and (b) mortality, primary treatment failure, infectious complications, and antibiotic adverse events for CAMERA2. For both trials, we additionally included length of stay or duration of antibiotic treatment as tiebreakers after the primary HCE in separate analyses. We applied these analytic methods: (a) logistic regression using a binary composite outcome, (b) generalized pairwise comparisons using different outcome permutations, (c) Wilcoxon rank sum approach for an ordinal outcome, (d) proportional odds model, and (e) probabilistic index model. We estimated the probabilistic index, win ratio, win odds, net treatment benefit, or odds ratio where possible using each method.

Results
For the BALANCE trial, all analyses of the primary HCE resulted in the same conclusion of no evidence of differences between treatment groups. Inclusion of length of stay as a tiebreaker resulted in 7 of 11 analyses finding the 7-day treatment arm superior to the 14-day arm, whereas inclusion of antibiotic duration resulted in all analyses concluding superiority of the 7-day treatment arm. For the CAMERA2 trial, all analyses found no evidence of differences between the two treatment groups. For all analyses, there were only minor differences in estimates across different analytic methods.

Conclusions
In these post hoc analyses, different methods for analysing HCEs resulted in similar effect estimates and conclusions consistent with the primary analyses of the BALANCE and CAMERA2 trials. These analyses illustrate how different HCEs can be constructed and analysed, and may be useful to other researchers in designing future studies that use HCEs.
Original languageEnglish
Pages (from-to)482-489
Number of pages8
JournalClinical Microbiology and Infection
Volume32
Issue number3
DOIs
Publication statusPublished - Feb 2026

Bibliographical note

Publisher Copyright:
© 2025 The Author(s).

Fingerprint

Dive into the research topics of 'Comparing different methods for analysing hierarchical composite endpoints: two illustrative case studies with post hoc analyses of the BALANCE (Bacteraemia Antibiotic Length Actually Needed for Clinical Effectiveness) and CAMERA2 (Combination Antibiotics for methicillin-resistant Staphylococcus aureus) randomized clinical trials'. Together they form a unique fingerprint.

Cite this